RLMD
Price
$0.57
Change
-$0.03 (-5.00%)
Updated
Aug 8, 10:36 AM (EDT)
Capitalization
19.98M
90 days until earnings call
SYRE
Price
$15.20
Change
-$0.04 (-0.26%)
Updated
Aug 8, 11:21 AM (EDT)
Capitalization
920.51M
90 days until earnings call
Interact to see
Advertisement

RLMD vs SYRE

Header iconRLMD vs SYRE Comparison
Open Charts RLMD vs SYREBanner chart's image
Relmada Therapeutics
Price$0.57
Change-$0.03 (-5.00%)
Volume$205
Capitalization19.98M
Spyre Therapeutics
Price$15.20
Change-$0.04 (-0.26%)
Volume$100
Capitalization920.51M
RLMD vs SYRE Comparison Chart in %
Loading...
RLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RLMD vs. SYRE commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RLMD is a Hold and SYRE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (RLMD: $0.60 vs. SYRE: $15.24)
Brand notoriety: RLMD and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RLMD: 22% vs. SYRE: 69%
Market capitalization -- RLMD: $19.98M vs. SYRE: $920.51M
RLMD [@Biotechnology] is valued at $19.98M. SYRE’s [@Biotechnology] market capitalization is $920.51M. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RLMD’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • RLMD’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, RLMD is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RLMD’s TA Score shows that 3 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • RLMD’s TA Score: 3 bullish, 6 bearish.
  • SYRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than RLMD.

Price Growth

RLMD (@Biotechnology) experienced а -3.29% price change this week, while SYRE (@Biotechnology) price change was -10.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Reported Earning Dates

RLMD is expected to report earnings on Nov 06, 2025.

SYRE is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($921M) has a higher market cap than RLMD($20M). RLMD YTD gains are higher at: 15.750 vs. SYRE (-34.536). RLMD has higher annual earnings (EBITDA): -79.12M vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. RLMD (27.1M). SYRE has less debt than RLMD: SYRE (0) vs RLMD (256K). RLMD (0) and SYRE (0) have equivalent revenues.
RLMDSYRERLMD / SYRE
Capitalization20M921M2%
EBITDA-79.12M-214.36M37%
Gain YTD15.750-34.536-46%
P/E RatioN/A1.72-
Revenue00-
Total Cash27.1M565M5%
Total Debt256K0-
FUNDAMENTALS RATINGS
RLMD vs SYRE: Fundamental Ratings
RLMD
SYRE
OUTLOOK RATING
1..100
7166
VALUATION
overvalued / fair valued / undervalued
1..100
19
Undervalued
75
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
4159
P/E GROWTH RATING
1..100
10083
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RLMD's Valuation (19) in the null industry is somewhat better than the same rating for SYRE (75) in the Pharmaceuticals Major industry. This means that RLMD’s stock grew somewhat faster than SYRE’s over the last 12 months.

RLMD's Profit vs Risk Rating (100) in the null industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that RLMD’s stock grew similarly to SYRE’s over the last 12 months.

RLMD's SMR Rating (99) in the null industry is in the same range as SYRE (99) in the Pharmaceuticals Major industry. This means that RLMD’s stock grew similarly to SYRE’s over the last 12 months.

RLMD's Price Growth Rating (41) in the null industry is in the same range as SYRE (59) in the Pharmaceuticals Major industry. This means that RLMD’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (83) in the Pharmaceuticals Major industry is in the same range as RLMD (100) in the null industry. This means that SYRE’s stock grew similarly to RLMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RLMDSYRE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 17 days ago
85%
Declines
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
RLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARTHX26.210.02
+0.08%
Artisan Global Equity Investor
JCVIX24.22N/A
N/A
JHancock Classic Value I
FZADX25.24N/A
N/A
Fidelity Advisor Dividend Growth Z
AIEMX11.90N/A
N/A
Alger Emerging Markets I
AEIUX8.79N/A
N/A
American Century Equity Income R5

RLMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLMD has been loosely correlated with SYRE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if RLMD jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLMD
1D Price
Change %
RLMD100%
+0.48%
SYRE - RLMD
36%
Loosely correlated
-4.51%
ENTO - RLMD
36%
Loosely correlated
-9.09%
PRTC - RLMD
31%
Poorly correlated
-1.70%
AVXL - RLMD
31%
Poorly correlated
+2.28%
ZVRA - RLMD
29%
Poorly correlated
+5.66%
More